Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are anticipating strong growth driven by the robust sales of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential challenges from rising costs,